Emerging therapeutic strategies to enhance HDL function

Lipids in Health and Disease

Review

Teresa Tejerina¹  Concha Urraca¹  Santiago Redondo²  José Martínez-González³ 

[1] Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, Spain;Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, Spain;Service of Hematology, Hospital Nuestra Señora de Sonsoles, Ávila, Spain;IIB-Sant Pau, Cardiovascular Research Center (CSIC-ICCC), Barcelona, Spain;

关键词: Atorvastatin;    Cholesterol Ester;    Cholesterol Efflux;    Reverse Cholesterol Transport;    Atheromatous Plaque;   

DOI  :  10.1186/1476-511X-10-175

 received in 2011-09-09, accepted in 2011-10-10,  发布年份 2011

来源: Springer

【 摘 要 】

Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and cardiovascular disease (CVD). The most relevant cardioprotective mechanism mediated by HDL is thought to be reverse cholesterol transport (RCT). New insights in HDL biology and RCT have allowed the development of promising agents aimed to increase HDL function and promote atherosclerosis regression. In this regard, apo-AI analogs and CETP inhibitors dalcetrapib and anacetrapib have aroused a great interest and opened new expectations in the treatment of CVD.

【 授权许可】

CC BY   
© Redondo et al; licensee BioMed Central Ltd. 2011